Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fluff and nonsense

This article was originally published in Scrip

Executive Summary

The analysts, who have words for these occurrences, will no doubt call it a correction or an adjustment. But whatever its name, the huge loss of market value in the pharmaceutical and biotechnology sector in the past week should alert those in the life science to the fact that some of the optimism about the recovery of the healthcare companies has evaporated. Investors in publically quoted pharmaceutical and biotechnology companies have decided in their herd-like wisdom that they are now much more uncertain in August about healthcare companies than they were in July, doubly so for those companies with unproven track records.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC014028

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel